Predictors of Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT)
Allogeneic hematopoietic cell transplant (HCT) is the treatment of choice for many severe life-threatening malignant or non-malignant diseases of the hematopoietic system. Despite significant improvement in survival after HCT, patients still suffer high mortality and morbidity risk from disease relapse or transplant-related complications.
Studies in the Clinical Genetics Branch aim to improve patient survival by identifying biomarkers that can guide donor selection or refine patient risk stratification. Ongoing research includes patients receiving HCT for severe aplastic anemia or myeloid neoplasms.
For more information, contact Shahinaz Gadalla.
Brown D et al. Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis. Nature Communications 2022.
Gadalla SM et al. Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study. Lancet Haematology 2020.